Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Moderna says FDA to review its flu vaccine after reversing course
Moderna says FDA to review its flu vaccine after reversing course
Megan Cerullo
Thu, February 19, 2026 at 2:06 AM GMT+9 2 min read
In this article:
MRNA
+5.51%
The U.S. Food and Drug Administration has reversed an earlier decision and said it will review drugmaker Moderna’s application for approval of a seasonal flu vaccine, the company said in a statement Wednesday.
The FDA’s Center for Biologics Evaluation and Research notified Moderna that the agency will allow the application for the vaccine candidate, mRNA-100, to proceed to review, the drugmaker said. The FDA didn’t immediately respond to a request for comment.
This marks a reversal for the FDA, which last week sent Moderna a so-called “refusal to file” letter rejecting the application. The dispute centered on a 40,000-person clinical trial that found Moderna’s new vaccine was more effective in adults aged 50 and older than one of the standard flu shots used today.
In the FDA’s rare “refusal to file” letter, vaccine director Dr. Vinay Prasad faulted the trial for not including another brand specifically recommended for people 65 and older.
In a high-priority, or “Type A,” meeting with the FDA, Moderna revised its application to seek full vaccine approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older. The drugmaker also agreed to conduct an additional study of the drug’s use by older adults.
The FDA is expected to make a decision by August, and Moderna said it aims to make the approved vaccine available to adults 50 and up for the 2026-27 flu season.
“We appreciate the FDA’s engagement in a constructive Type A meeting and its agreement to advance our application for review,” Moderna chief executive Stéphane Bancel said in a statement Wednesday. “Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu.”
The vaccine candidate is also under review in Europe, Canada and Australia.
Shares of Moderna rose $2.57, or 5.9%, to $46.50 in late morning trading.
Oscar-winning actor Robert Duvall dies at 95
John Shirreffs & Zenyatta | 60 Minutes Archive
Sneak peek: Cati Blauvelt: Death of a Soldier’s Wife
Terms and Privacy Policy
Privacy Dashboard
More Info